New therapy silences hepatitis B in 98% of infected liver cells without cutting DNA
Existing hepatitis B drugs only suppress viral replication; they cannot clear the viral DNA lodged in the cell nucleus. A new therapy uses engineered dCas9 to mark viral DNA with permanent methylation tags, rendering it completely silent within hepatocytes.
The video won't play here. Listen to the audio instead:
The argument · tap a timestamp to hear it
Fetal loss rate exceeds the facility baseline—from 2.6% to 18%
Eleven late-gestation macaques were infected with high-dose H1N1 via simultaneous nasal, tracheal, ocular, and oral inoculation; four showed no symptoms throughout, two showed severe illness, including one (Blue Nine) with fetal loss. The facility's six-year baseline shows 2.6% fetal loss; this study recorded 2 losses in 11 pregnancies (at gestational days 134 and 121, roughly 78% of term at ~172 days). Maternal viral load remained confined to lungs; no virus detected in plasma.
— KathyVirus never reaches fetus; placenta still sounds antiviral alarm
Only two cases showed low-copy viral RNA in placental villi; fetal brain, spinal cord, heart, liver, spleen, and other tissues tested negative—no vertical transmission. Yet placental villi showed marked elevation in IL-1β, IL-18, and interferon-β; 185 genes upregulated and 178 downregulated, indicating placental antiviral response. The signal crossing the placental barrier remains unknown, and researchers identify this as a question for future work.
Severe maternal illness disrupts fetal immune development despite viral containment
Greater maternal lung disease severity and higher type I interferon levels correlated with larger shifts in fetal immune populations—CD8 T cells, dendritic cells—even though virus never entered fetal tissue. Researchers emphasized this finding should not be read as ‘pregnancy immune activation itself is dangerous,’ but rather shows that vaccination to prevent maternal severe illness is the most direct path to preventing fetal immune dysregulation.
— BriannaHepatitis B drugs suppress virus but cannot clear its DNA
Approximately 250 million people globally carry hepatitis B; roughly one million die yearly from cirrhosis and hepatocellular carcinoma, yet the disease receives almost no media coverage except when antivaccination rhetoric invokes it. Frontline drugs (nucleoside/nucleotide analogs, or ‘nukes’) inhibit viral replication and reduce cirrhosis and cancer risk, but cannot eliminate cccDNA from the cell nucleus, cannot remove integrated viral DNA in the host genome, and cannot suppress surface antigen production. Patients typically require lifelong therapy similar to HIV-infected individuals.
Therapy labels hepatitis DNA for permanent epigenetic silencing without cutting
Crema 1001's core mechanism is an entirely artificial fusion protein: catalytically dead Cas9 (binds but does not cut DNA) plus a KRAB transcription-inhibiting domain plus a methylation-effector domain, directed by guide RNA to precise landing sites on the hepatitis B genome. Researchers screened 121 candidate guide RNAs and identified 51 that reduced antigen by more than 50%; they selected gRNA2 for its best compatibility across viral genotypes. The entire mechanism leverages CRISPR's targeting capability while avoiding its cutting function entirely.
— KathySingle injection drives 98% of hepatocytes to viral antigen negativity
In transgenic mice carrying two integrated copies of the complete hepatitis B genome, a single dose reduced surface antigen up to 2.7 logs and viral DNA by 2.9 logs, with effects sustained through seven months of monitoring. Eleven of fifteen mice showed antigen below the detection limit; the highest-dose cohort achieved 98% of hepatocyte nuclei negative for core antigen by immunostaining. The integrated viral DNA remained intact and unchanged—only permanently silenced, not excised.
— KathyDrug clears in seven days; viral silencing persists indefinitely
Guide RNA and effector protein mRNA peaked at twenty-four hours post-injection but were undetectable by day seven; viral DNA methylation marks peaked on day three and persisted through the end of the observation period. Prior studies demonstrate such methylation marks remain stable for over one year in mice and nonhuman primates—the therapeutic drug clears rapidly, but the silencing switch is transmitted through cell division to subsequent generations.
— RichOff-target screening flags 1591 sites; validation confirms zero misfires
Computational prediction using up to four mismatches identified 1591 potential guide RNA off-target sites in hepatocytes, splenic endothelial cells, and adrenocortical cells. Sequential validation found abnormal methylation at only four sites, and none showed corresponding gene expression changes; therefore, researchers concluded there were no ‘verified unintended targets.’ Investigators acknowledged testing only one donor per cell type and not screening germ cells, anticipating additional regulatory requirements.
— KathyIn their own words · checked verbatim
The placenta knows there's an infection going on.
the more severe the infection is, the more change is happening in the baby's immune response
Brianna29:26
our data suggests that immunologic rather than virologic signals are responsible for profound changes in the fetal immune landscape
Expression and DNA methylation profiling revealed no detectable unintended targets in the human genome and Creme 1001 induced transient liver transaminase elevations only at the very highest dose tested.
Kathy45:40
Hepatitis B, 250 million people infected, a million deaths a year, and nobody talks about it.
So this is a totally cooked up protein, right? Totally cooked up.
Rich51:43
This is going away very very quickly.
Figures
| Global hepatitis B infections | 250 million | 46:40 |
| Initial guide RNA screening pool | 121 | 39:37 |
| Guide RNAs achieving >50% antigen reduction | 51 | 57:50 |
| Maximum surface antigen reduction in transgenic mice | 2.7 log | 1:03:53 |
| Maximum viral DNA reduction in transgenic mice | 2.9 log | 1:03:53 |
| Highest-dose cohort hepatocytes core antigen-negative | 98% | 1:04:53 |
| Predicted guide RNA off-target genomic sites | 1591 | 1:16:04 |
| Fetal loss rate in infected pregnant macaques | 2/11 | 16:19 |
| U.S. pregnant women flu vaccination rate | approximately one-half | 33:29 |
Glossary
- cccDNA
- covalently closed circular DNA; the free-floating viral DNA form in infected liver cell nuclei serving as the source of continuous viral production and antigen synthesis
- dCas9
- catalytically dead Cas9; engineered Cas9 protein that binds DNA but lacks cutting ability
- epigenetic silencing
- inactivating gene transcription through DNA methylation and related modifications without altering the underlying DNA sequence
- nucleoside/nucleotide analogs (nukes)
- frontline hepatitis B antivirals that suppress viral replication but cannot eliminate viral DNA or suppress antigen production
- VUT (verified unintended target)
- a genomic site with both abnormal methylation and measurable gene expression changes—a confirmed off-target effect
- guide RNA
- short RNA molecule directing Cas9-family proteins to bind at precise target DNA sequences
How to listen
Pharma researchers and investors tracking hepatitis B and gene therapy; clinicians and public-health professionals interested in immune responses to viral infection during pregnancy.
Listener mail and personal recommendations after the 83-minute mark have minimal connection to the papers and can be skipped.